Rosen E M, Fan S, Goldberg I D, Rockwell S
Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, New York, USA.
Oncology (Williston Park). 2000 May;14(5):741-57; discussion 757-8, 761-6.
Recent studies have elucidated some of the molecular and cellular mechanisms that determine the sensitivity or resistance to ionizing radiation. These findings ultimately may be useful in devising new strategies to improve the therapeutic ratio in cancer treatment. Despite the rapid advances in knowledge of cellular functions that affect radiosensitivity, we still cannot account for most of the clinically observed heterogeneity of normal tissue and tumor responses to radiotherapy, nor can we accurately predict which individual tumors will be controlled locally and which patients will develop more severe normal tissue damage after radiotherapy. However, several candidate genes for which deletion or loss of function mutations may be associated with altered cellular radiosensitivity (e.g., ATM, p53, BRCA1, BRCA2, DNA-PK) have been identified. Some of the differences in normal tissue sensitivity to radiation may stem from mutations with milder effects, heterozygosity, or polymorphisms of these genes. Finally, molecular mechanisms linking genetic instability, radiosensitivity, and predisposition to cancer are being unraveled.
最近的研究已经阐明了一些决定对电离辐射敏感性或抗性的分子和细胞机制。这些发现最终可能有助于设计新的策略来提高癌症治疗中的治疗比率。尽管在影响放射敏感性的细胞功能知识方面取得了快速进展,但我们仍然无法解释临床上观察到的正常组织和肿瘤对放疗反应的大多数异质性,也无法准确预测哪些个体肿瘤将在局部得到控制,以及哪些患者在放疗后会出现更严重的正常组织损伤。然而,已经鉴定出几个候选基因,其缺失或功能丧失突变可能与细胞放射敏感性改变有关(例如,ATM、p53、BRCA1、BRCA2、DNA-PK)。正常组织对辐射敏感性的一些差异可能源于这些基因具有较温和效应的突变、杂合性或多态性。最后,将遗传不稳定、放射敏感性和癌症易感性联系起来的分子机制正在被揭示。